Saudi Arabia has signed two deals to improve the treatment and prevention of diabetes.

Memorandums of understanding were agreed with German pharmaceutical firm Boehringer Ingelheim and the Danish healthcare company Novo Nordisk at the Riyadh Global Medical Biotechnology Summit earlier this week.

They aim to boost cooperation with the biotech and pharmaceutical sector, localize manufacturing, raise awareness and establish research centers in the Kingdom.

Under its deal, Boehringer Ingelheim will increase the manufacture of medicine used to treat type 2 diabetes and diagnose rare diseases in the Kingdom.